Ascendis Pharma A
Insiders
Last 12 monthsSales planned on beside the trades reported on , and whether each names a .
Planned ·
$105.9M
27 notices · 466,404 sh
Oct 2025 to Oct 2026
Reported ·
$4,641,015
1 sale · 7 buys · $284,414 bought
Oct 2025 to Jun 2026
The two figures cover different periods.
The one reported sale does not carry the 10b5-1 box. It is 0.03% of the shares on issue.
under a no plan named▼ sale▲ buysize is dollars
Form 144 notices, newest first
2026-09-08Bodenhoff Mads, SVP & PAO$810,563
2026-09-02HOLTUG LARS, Director$62,335
2026-05-11JENSEN FLEMMING STEEN, See Remarks$4,641,022
Form 4, 2026-05-12: sold 19,460 at $238.49 Form 4 ↗
2026-03-09SINGEL STINA, Officer$907,680
2026-03-06Bodenhoff Mads, SVP & PAO$2,375,308
2026-03-05SMITH SCOTT THOMAS, EVP & Chief Financial Officer$2,400,000
2026-03-05Jan Moller Mikkelsen, CEO, Officer$22.7M
2026-03-05Shu Aimee, EVP & Chief Medical Officer$1,316,555
2026-03-04Shu Aimee, EVP & Chief Medical Officer$1,743,914
2026-03-04Morrison Lisa, Officer$2,388,195
2026-03-02Fairey William, Director$435,762
2026-03-02IMANI SIHAM, Director$435,762
2026-03-02SMITH SCOTT THOMAS, EVP & Chief Financial Officer$4,442,109
2026-03-02JENSEN MICHAEL WOLFF, EVP, Chief Legal Officer$4,442,109
2026-03-02Bodenhoff Mads, SVP & PAO$1,663,642
2026-03-02PEDERSEN ANNI LOTTE KIRSTINE SONDERBJERG, EVP & Chief Admin Officer$2,614,572
2026-03-02Morrison Lisa, Director$508,389
2026-03-02HOLTUG LARS, Director$508,389
2026-03-02SPROGOE KENNETT, See Remarks$2,614,572
2026-03-02JENSEN FLEMMING STEEN, See Remarks$2,614,572
2026-03-02Cha Albert, Director$508,389
2026-01-13MIKKELSEN JAN MOLLER, Officer, PRESIDENT CEO$18.4M
2025-12-04JENSEN MICHAEL WOLFF, EVP, Chief Legal Officer$2,081,019
2025-12-02Jan Moller Mikkelsen, CEO, Officer$21.1M
2025-12-02SPROGOE KENNETT, See Remarks$2,093,222
2025-12-02JENSEN FLEMMING STEEN, See Remarks$2,058,454
2025-12-01SINGEL STINA, Officer$45,680